<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782733/" ref="ordinalpos=4582&amp;ncbi_uid=2165189&amp;link_uid=PMC2782733" image-link="/pmc/articles/PMC2782733/figure/F2/" class="imagepopup">Fig. 2.  From: Pharmacotherapy for Adults with Tumors of the Central Nervous System. </a></div><br /><div class="p4l_captionBody">EGFR signaling through the PI3K/Akt pathway. Erlotinib and gelfitinib interfere with autophosphorylation of EGFR. In tumors that exhibit upregulation of IGFR, signaling of that receptor through Ras/Raf can bypass the block and generate sufficient activated PI3K to signal through Akt; these tumors are therefore resistant to erlotinib and gelfitinib. Adjunctive treatment with farnesyl transferase inhibitors or nelfinavir can overcome this resistance.</div></div>